Rebecca Rogers
Research Subjects
Rebecca Rogers has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Cano
Modus Outcomes Ltd Cheltenham UK
2 shared publications Annabelle Monnet
F. Hoffmann-La Roche Ltd., Basel, Switzerland
1 shared publicationDanny Bega
Northwestern Medicine, Neurology (Movement Disorders), Chicago, IL, USA
1 shared publicationDeborah A Hall
Rush University, Department of Neurological Sciences, Chicago, IL, USA
1 shared publication- Dylan Trundell
Roche Products Ltd, Welwyn Garden City, UK
1 shared publication - Emma Elliott
NIHR-ARC Greater Manchester, School of Health Sciences, The University of Manchester, The University of Manchester, Manchester, UK
1 shared publication
Latest Publications
- Open Access
- 22 July 2025
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 14 (4) , 369-381
Reliability and validity of the Huntington's Disease Everyday Functioning (Hi-DEF): A patient-reported measure of cognitive capacity on daily functioning in Huntington's disease
Background: The Huntington's Disease (HD) Everyday Functioning (Hi-DEF) is a novel patient-reported outcome (PRO) scale developed to assess the impact of cognitive impairment on daily functioning in early HD patients. Objective: To examine the psychometric properties, including reliability and validity, of the Hi-DEF. Findings from psychometric analyses using classical test theory (CTT) approach are presented here. Methods: A non-interventional validation study was conducted across nine HD Centers of Excellence across the US. Results: Patients with HD (n = 151) were recruited: 59% were female, mean (SD) age was 47 (12) years, and mean (range) Total Functional Capacity (TFC) score was 11.4 (8–13). Excellent internal consistency reliability was observed for the Hi-DEF scale total score (Cronbach's alpha: 0.98) and across subscales (alpha range 0.87–0.96). Most targeting and scaling assumptions were met, although there were ceiling effects for three subscales. Construct validity was demonstrated by moderate to high Spearman's rank-order correlations with TFC scores (range r = −0.38 to −0.62) and known and validated measures such as the HD-PRO-TRIAD TM (range r = 0.75–0.90), and ability to discriminate between levels of functional impairment (TFC 13, 12–11, and 10–8; p < 0.001). Correlations with Cambridge Neuropsychological Test Automated Battery (CANTAB) cognitive performance measures were low to moderate and ranged from 0.06 to 0.38. Conclusions: The Hi-DEF is a reliable and valid PRO scale measuring the impact of cognitive impairment on daily functioning, assessing facets of cognitive functioning in context of activities of daily living impacted in early stages of HD.
- 22 July 2025
- Published by SAGE Publications in Journal of Huntington's Disease
- Vol. 14 (4) , 369-381
Open AccessReliability and validity of the Huntington's Disease Everyday Functioning (Hi-DEF): A patient-reported measure of cognitive capacity on daily functioning in Huntington's disease
Background: The Huntington's Disease (HD) Everyday Functioning (Hi-DEF) is a novel patient-reported outcome (PRO) scale developed to assess the impact of cognitive impairment on daily functioning in early HD patients. Objective: To examine the psychometric properties, including reliability and validity, of the Hi-DEF. Findings from psychometric analyses using classical test theory (CTT) approach are presented here. Methods: A non-interventional validation study was conducted across nine HD Centers of Excellence across the US. Results: Patients with HD (n = 151) were recruited: 59% were female, mean (SD) age was 47 (12) years, and mean (range) Total Functional Capacity (TFC) score was 11.4 (8–13). Excellent internal consistency reliability was observed for the Hi-DEF scale total score (Cronbach's alpha: 0.98) and across subscales (alpha range 0.87–0.96). Most targeting and scaling assumptions were met, although there were ceiling effects for three subscales. Construct validity was demonstrated by moderate to high Spearman's rank-order correlations with TFC scores (range r = −0.38 to −0.62) and known and validated measures such as the HD-PRO-TRIAD TM (range r = 0.75–0.90), and ability to discriminate between levels of functional impairment (TFC 13, 12–11, and 10–8; p < 0.001). Correlations with Cambridge Neuropsychological Test Automated Battery (CANTAB) cognitive performance measures were low to moderate and ranged from 0.06 to 0.38. Conclusions: The Hi-DEF is a reliable and valid PRO scale measuring the impact of cognitive impairment on daily functioning, assessing facets of cognitive functioning in context of activities of daily living impacted in early stages of HD.
- Open Access
- 14 January 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (1) , 97-110
Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III
Background: To understand changes in the underlying progression of early Parkinson's disease, it is important to derive estimates of the threshold for meaningful motor progression on the MDS-UPDRS Part III in OFF medication state. Objective: To estimate this threshold using two approaches: anchor-based analyses, and clinical consensus via a modified Delphi panel. Methods: For the anchor-based analyses, data from a Phase II clinical trial were used. Mean and median MDS-UPDRS Part III change scores were calculated for those participants rated as ‘Minimally worse’ on the Clinical Global Impression of Improvement (using the first visit rated as ‘Minimally worse’ or worse, and at Weeks 24 and 52). Cumulative data up to Week 104 were used to assess the difference between motor progressors’ and non-progressors’ change scores on motor-related outcomes. For the modified Delphi panel, a panel of 13 expert clinicians received an online survey in two rounds and provided responses anonymously. Results: For the anchor-based analyses, estimates of meaningful change ranged from 4−6 points. Numerically worse change scores were identified on motor-related outcomes for participants who had experienced motor progression compared with those who had not. For the modified Delphi panel, consensus was reached in Round 2, with 92% agreeing that 5 points is suitable to define a clinically meaningful motor progression threshold. Conclusions: Results of the anchor-based analyses and modified Delphi panel were consistent, supporting a meaningful motor progression threshold of a worsening of 5 points on the MDS-UPDRS Part III (OFF medication state) in an early Parkinson's disease population.
- 14 January 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (1) , 97-110
Open AccessEstimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III
Background: To understand changes in the underlying progression of early Parkinson's disease, it is important to derive estimates of the threshold for meaningful motor progression on the MDS-UPDRS Part III in OFF medication state. Objective: To estimate this threshold using two approaches: anchor-based analyses, and clinical consensus via a modified Delphi panel. Methods: For the anchor-based analyses, data from a Phase II clinical trial were used. Mean and median MDS-UPDRS Part III change scores were calculated for those participants rated as ‘Minimally worse’ on the Clinical Global Impression of Improvement (using the first visit rated as ‘Minimally worse’ or worse, and at Weeks 24 and 52). Cumulative data up to Week 104 were used to assess the difference between motor progressors’ and non-progressors’ change scores on motor-related outcomes. For the modified Delphi panel, a panel of 13 expert clinicians received an online survey in two rounds and provided responses anonymously. Results: For the anchor-based analyses, estimates of meaningful change ranged from 4−6 points. Numerically worse change scores were identified on motor-related outcomes for participants who had experienced motor progression compared with those who had not. For the modified Delphi panel, consensus was reached in Round 2, with 92% agreeing that 5 points is suitable to define a clinically meaningful motor progression threshold. Conclusions: Results of the anchor-based analyses and modified Delphi panel were consistent, supporting a meaningful motor progression threshold of a worsening of 5 points on the MDS-UPDRS Part III (OFF medication state) in an early Parkinson's disease population.